Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate

OBJECTIVE(S): One of the important interactions in controlling the human immune system is the reaction between checkpoint proteins such as programmed cell death-1 (PD-1) and its ligand, PD-L1. These are negative immunoregulatory molecules that promote immune evasion of tumor cells. PD-L1 expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Oghalaie, Akbar, Mahboudi, Fereidoun, Rahimi-Jamnani, Fatemeh, Piri-Gavgani, Somayeh, Kazemi-Lomedasht, Fatemeh, Hassanzadeh Eskafi, Ayda, Shahbazzadeh, Delavar, Adeli, Ahmad, Talebkhan, Yeganeh, Behdani, Mahdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148396/
https://www.ncbi.nlm.nih.gov/pubmed/35656179
http://dx.doi.org/10.22038/IJBMS.2022.62522.13834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148396/
https://www.ncbi.nlm.nih.gov/pubmed/35656179
http://dx.doi.org/10.22038/IJBMS.2022.62522.13834

Ejemplares similares